Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Successful fidaxomicin hospital discharges of adult patients with Clostridioides difficile infections post 2021 guidelines - are economic barriers finally coming down? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Fang, N., Ha, D., Dong, K., Leung, T., Lee, S., Holubar, M., Meng, L. 1800
Abstract
We reviewed C.difficile positive patients discharged on fidaxomicin after local adoption of 2021C.difficile infection (CDI) guidelines. From June 14 - Oct 3, 2021, 80% (12/15) had copayments $0-$35, and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.
View details for DOI 10.1093/cid/ciab1061
View details for PubMedID 34971358